GlassScriptPhysician profile
Nicolas Gabriel Biro
NPI 1497959332
$76,163.03
in general payments reported to CMS, 2019-2025
20 companies · $26K in 2025
The $26K reported for 2025 was more than what 96% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
See the full distribution for Ophthalmic Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $303 · 2021: $165 · 2022: $2,131 · 2023: $39K · 2024: $7,635 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $37K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Consulting Fee: $5,100 · Food and Beverage: $3,585 · Travel and Lodging: $2,510 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $36,512.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,500.00 |
| Consulting Fee | $5,100.00 |
| Food and Beverage | $3,584.59 |
| Travel and Lodging | $2,510.06 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $41,098.94 | 2020-2023 | Tepezza |
| Amgen INC. | $33,582.85 | 2024-2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $294.20 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $230.73 | 2019-2023 | Cequa |
| Sight Sciences, INC. | $160.83 | 2022 | |
| Oyster Point Pharma, INC. | $124.21 | 2022 | |
| Glaukos Corporation | $93.14 | 2025 | Idosetr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $76.16 | 2019 | |
| Allergan, INC. | $74.99 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $71.73 | 2025 | Xdemvy |
| Galderma Laboratories, L.P. | $66.27 | 2019 | |
| Biotissue Holdings INC. | $60.26 | 2022 | |
| Novartis Pharmaceuticals Corporation | $44.07 | 2020-2021 | |
| Regeneron Pharmaceuticals, INC. | $39.96 | 2021 | |
| Alcon Vision LLC | $34.25 | 2024 | Rocklatan |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $24.31 | 2021 | |
| Abbvie INC. | $23.62 | 2022 | |
| Mallinckrodt Enterprises LLC | $22.83 | 2019 | |
| Alexion Pharmaceuticals, INC. | $20.28 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolas Biro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.